GlassScriptPhysician profile
Sam N Russo
NPI 1023468733
$2,454.50
in general payments reported to CMS, 2019-2025
21 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $36.78 · 2021: $97.70 · 2022: $144 · 2023: $666 · 2024: $672 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $948.00 | 2022-2025 | Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $349.40 | 2022-2025 | |
| Biogen, INC. | $210.01 | 2021-2025 | Skyclarys |
| Amgen INC. | $143.02 | 2019 | |
| Genzyme Corporation | $122.42 | 2025 | |
| Acadia Pharmaceuticals INC | $86.46 | 2021-2025 | Daybue |
| Neurocrine Biosciences, INC. | $80.60 | 2023-2024 | Ingrezza, Ongentys |
| Upsher-Smith Laboratories LLC | $77.89 | 2021-2024 | |
| Immedica Pharma US, INC. | $71.37 | 2023-2024 | |
| Ptc Therapeutics, INC. | $56.39 | 2021-2023 | |
| Sk Life Science, INC. | $52.62 | 2023 | |
| Aucta Pharmaceuticals, INC. | $46.22 | 2024-2025 | Motpoly Xr |
| Acorda Therapeutics, INC | $43.39 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $31.84 | 2020-2021 | |
| Eisai INC. | $24.82 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $24.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.90 | 2023 | |
| Aprecia Pharmaceuticals, LLC | $22.16 | 2024 | Spritam |
| Avanir Pharmaceuticals, INC. | $19.80 | 2019 | |
| Neurelis, INC. | $19.39 | 2023 | Valtoco |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.